Doug Solomon is a Managing Director in Barclays’ Global Healthcare Group, and manages and originates the firm’s medical technology business, a position he held at Lehman Brothers prior to its acquisition by Barclays. Prior to his role in medical technology banking, Doug was a senior member of the healthcare mergers and acquisitions practice at Lehman Brothers, executing transactions across various healthcare sub-verticals, including medical technology and life sciences.
During his nearly 20 years in investment banking at Barclays/Lehman Brothers, Doug has led the execution of numerous M&A and capital markets transactions.
Selected M&A experience includes Boston Scientific’s pending acquisition of BTG plc for $4.2 billion, Syneron’s sale to Apax Partners for ~$400 million, Allergan’s acquisition of LifeCell for $2.9 billion, Sage Products sale to Stryker for $2.775 billion, Welch Allyn’s sale to Hill-Rom for $2.05 billion, CareFusion’s sale to Becton Dickinson for $12.2 billion, Abbott’s acquisition of CFR Pharmaceuticals for $3.3 billion, Given Imaging’s sale to Covidien for $860 million, Stryker’s acquisition of Trauson for $685 million, the sale of Fenwal to Fresenius ($1.1 billion), Covidien’s acquisition of Oridion for $300 miilion, Fujifilm’s acquisition of SonoSite for $995 million, Stryker’s $1.5 billion acquisition of Boston Scientific’s neurovascular business, the $625 million sale of Datascope to Getinge AB, Centerpulse AGs $3.6 billion sale to Zimmer, the $3.9 billion merger of Apogent Technologies with Fisher Scientific, Esperion’s $1.3 billion sale to Pfizer and the $26 billion merger of CVS and Caremark.
Doug earned his MBA from Columbia Business School and a BBA from Hofstra University.